choose an OSM over a TNFi biologic may include mild-to-moderate disease, a preference of oral over parenteral therapy, or concerns regarding adverse effects of a biologic. A TNFi biologic would not be a good choice in patients with contraindications, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. During the development of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations In patients with